Through our commitment to patients with unmet needs, we’re raising awareness about HER2-positive biliary tract cancer (BTC), an aggressive type of cancer often associated with a poor prognosis. As we continue to focus on those for whom we can have the greatest impact, HER2-positive cancers are one area we’re applying the science by investigating and developing innovative solutions for patients.

Our presence at SABCS 2023 marks a significant step forward for Jazz as our oncology pipeline continues to evolve to address new tumor types such as breast cancer. We’re excited to gather with leaders in the breast cancer community and share our research, including findings for our HER2-targeted bispecific antibody in HER2+ breast cancer, which reflects our continuous dedication to reshaping cancer care and addressing unmet needs. 

Recently, Mat Davis, PhD, vice president and head of data science, presented at the 2023 STAT Summit where he shared a key moment in his career when he learned the necessity of breaking down silos to fully embrace quantitative experts across the three avenues of drug development.

As World Heart Day approaches, we are reminded of people who live with complex sleep disorders and how we can adequately address their unique needs. Learn more about the importance of thinking holistically about narcolepsy and idiopathic hypersomnia patients’ health from Jazz’s Dr. Kelvin Tan and Dr. Logan Schneider of the Stanford University School of Medicine.

As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023. 

As we gear up for ASCO 2023, our team at Jazz is energized by the opportunity to share our research and learn about the latest advancements in cancer care, including difficult-to-treat cancers like small cell lung cancer (SCLC). It’s also an opportunity to highlight the importance of incorporating patients’ perspectives into our R&D process and supporting them and their families beyond treatment.